Evidence map›Paper›PMID 33057391›Full record

ArticlePLoS medicine2020

Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis.

Kanako Teramoto, Mário Santos, Brian Claggett, Jenine E John, Scott D Solomon, Dalane Kitzman, Aaron R Folsom, Mary Cushman, Kunihiro Matsushita, Hicham Skali and 1 more

Open access · goldAbstract read
In one paragraph

Article in PLoS medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Can Pulmonary Arterial Compliance Be a Prognostic Marker for Pulmonary Hypertension?American journal of respiratory and critical care medicine · 2023
    Article
  4. Observational
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Kanako TeramotoDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.ORCID 0000-0002-4217-9497
Mário SantosDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
Brian ClaggettDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
Jenine E JohnDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.ORCID 0000-0002-7174-9858
Scott D SolomonDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
Dalane KitzmanWake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America.
Aaron R FolsomDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, United States of America.ORCID 0000-0003-2635-2699
Mary CushmanDepartment of Medicine, University of Vermont, Burlington, Vermont, United States of America.ORCID 0000-0002-7871-6143
Kunihiro MatsushitaDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.ORCID 0000-0002-7179-718X
Hicham SkaliDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.ORCID 0000-0002-5629-4138
Amil M ShahDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.ORCID 0000-0003-1056-4451
Brigham and Women's Hospital · USJohns Hopkins University · USUniversity of Minnesota · USUniversity of Vermont · USWake Forest University · US

Funding

Epidemiology of Venous Thrombosis & Pulmonary EmbolismR01HL059367 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI TANG, WEIHONG · 1998 to 2024
$11.8M
Mapping the Progression to HFpEF in the Elderly through Longitudinal Changes in Cardiac FunctionR01HL135008 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI Amil M Shah · 2017 to 2026
$11.5M
Noninvasive Cardiovascular Imaging Research Training ProgramT32HL094301 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Marcelo F DI CARLI · 2010 to 2026
$7.8M
Early Detection of Transthyretin Cardiac Amyloidosis: Defining a Novel Target for HFpEF Treatment and Prevention in Late LifeR01HL150342 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI DORBALA, SHARMILA, SHAH, AMIL M · 2020 to 2023
$4.1M
Quantifying cardiac structure and function to define the progression to hear failure in African AmericansR01HL143224 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI SHAH, AMIL M · 2018 to 2021
$3.4M
Proteomic signatures to identifypathways underlying the progression toheart failureR01HL148218 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI SHAH, AMIL M, YU, BING · 2020 to 2023
$3.4M
Mentoring patient-oriented research in deep phenotyping of cardiac function for heart failure preventionK24HL152008 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI SHAH, AMIL M · 2020 to 2024
$608k
NHLBI NIH HHS HHSN268201100005CNHLBI NIH HHS HHSN268201100005GNHLBI NIH HHS HHSN268201100005INHLBI NIH HHS HHSN268201100006CNHLBI NIH HHS HHSN268201100007CNHLBI NIH HHS HHSN268201100007INHLBI NIH HHS HHSN268201100008CNHLBI NIH HHS HHSN268201100008INHLBI NIH HHS HHSN268201100009CNHLBI NIH HHS HHSN268201100009INHLBI NIH HHS HHSN268201100010CNHLBI NIH HHS HHSN268201100011CNHLBI NIH HHS HHSN268201100011INHLBI NIH HHS HHSN268201100012CNHLBI NIH HHS K24 HL152008NHLBI NIH HHS R01 HL059367NHLBI NIH HHS R01 HL135008NHLBI NIH HHS R01 HL143224NHLBI NIH HHS R01 HL148218NHLBI NIH HHS R01 HL150342NHLBI NIH HHS T32 HL094301
6 · The paper itself

Abstract

backgroundHeart failure (HF) risk is highest in late life, and impaired pulmonary vascular function is a risk factor for HF development. However, data regarding the contributors to and prognostic importance of pulmonary vascular dysfunction among HF-free elders in the community are limited and largely restricted to pulmonary hypertension. Our objective was to define the prevalence and correlates of abnormal pulmonary pressure, resistance, and compliance and their association with incident HF and HF phenotype (left ventricular [LV] ejection fraction [LVEF] ≥ or < 50%) independent of LV structure and function. METHODS AND

findingsWe performed cross-sectional and time-to-event analyses in a prospective epidemiologic cohort study, the Atherosclerosis Risk in Communities study. This is an ongoing, observational study that recruited 15,792 persons aged 45-64 years between 1987 and 1989 (visit 1) from four representative communities in the United States: Minneapolis, Minnesota; Jackson, Mississippi; Hagerstown, Maryland; and Forsyth County, North Carolina. The current analysis included 2,810 individuals aged 66-90 years, free of HF, who underwent echocardiography at the fifth study visit (June 8, 2011, to August 28, 2013) and had measurable tricuspid regurgitation by spectral Doppler. Echocardiography-derived pulmonary artery systolic pressure (PASP), pulmonary vascular resistance (PVR), and pulmonary arterial compliance (PAC) were measured. The main outcome was incident HF after visit 5, and key secondary end points were incident HF with preserved LVEF (HFpEF) and incident HF with reduced LVEF (HFrEF). The mean ± SD age was 76 ± 5 years, 66% were female, and 21% were black. Mean values of PASP, PVR, and PAC were 28 ± 5 mm Hg, 1.7 ± 0.4 Wood unit, and 3.4 ± 1.0 mL/mm Hg, respectively, and were abnormal in 18%, 12%, and 14%, respectively, using limits defined from the 10th and 90th percentile limits in 253 low-risk participants free of cardiovascular disease or risk factors. Left heart dysfunction was associated with abnormal PASP and PAC, whereas a restrictive ventilatory deficit was associated with abnormalities of PASP, PVR, and PAC. PASP, PVR, and PAC were each predictive of incident HF or death (hazard ratio per SD 1.3 [95% CI 1.1-1.4], p < 0.001; 1.1 [1.0-1.2], p = 0.04; 1.2 [1.1-1.4], p = 0.001, respectively) independent of LV measures. Elevated pulmonary pressure was predictive of incident HFpEF (HFpEF: 2.4 [1.4-4.0, p = 0.001]) but not HFrEF (1.4 [0.8-2.5, p = 0.31]). Abnormal PAC predicted HFrEF (HFpEF: 2.0 [1.0-4.0, p = 0.05], HFrEF: 2.8 [1.4-5.5, p = 0.003]), whereas abnormal PVR was not predictive of either (HFpEF: 0.9 [0.4-2.0, p = 0.85], HFrEF: 0.7 [0.3-1.4, p = 0.30],). A greater number of abnormal pulmonary vascular measures was associated with greater risk of incident HF. Major limitations include the use of echo Doppler to estimate pulmonary hemodynamic measures, which may lead to misclassification; inclusions bias related to detectable tricuspid regurgitation, which may limit generalizability of our findings; and survivor bias related to the cohort age, which may result in underestimation of the described associations.

conclusionsIn this study, we observed abnormalities of PASP, PVR, and PAC in 12%-18% of elders in the community. Higher PASP and lower PAC were independently predictive of incident HF. Abnormally high PASP predicted incident HFpEF but not HFrEF. These findings suggest that impairments in pulmonary vascular function may precede clinical HF and that a comprehensive pulmonary hemodynamic evaluation may identify pulmonary vascular phenotypes that differentially predict HF phenotypes.

Indexed as

AgedAged, 80 and overAtherosclerosisCohort StudiesCross-Sectional StudiesFemaleHeart FailureHeart VentriclesHumansMalePrevalencePrognosisProspective StudiesStroke VolumeUnited StatesVentricular Function, Left

Identifiers

PMID33057391
PMCPMC7561082
OpenAlexW3093345710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.